Positron emission tomography (PET) using @entity419 ( @entity419 ) is the best noninvasive imaging technique for to assess response in @entity1 suffering from @entity706 . Early response evaluation ("interim PET") after one, a few cycles, or at midtreatment can predict response, progression-free survival, and overall survival. We calculated from data of 7 studies an overall sensitivity to predict treatment failure of 79%, a specificity of 92%, a positive predictive value ( @entity2286 ) of 90%, a negative predictive value (NPV) of 81%, and an accuracy of 85%. Although it is not yet indicated to change @entity1 management based on residual @entity419 uptake on interim scan in chemotherapy-sensitive @entity1 , prospective studies evaluating the role of an interim PET in @entity1 management clearly are warranted. @entity419 PET also has an important prognostic role in relapsing @entity1 after reinduction chemotherapy before high-dose chemotherapy (HCT) followed by autologous stem cell transplantation (ASCT). However, all chemotherapy-sensitive @entity1 remain candidates for HCT followed by ASCT, even if @entity419 PET showed residual @entity419 uptake. We calculated from data of 3 studies an overestimated risk of relapse in 16% of all PET-positive @entity1 . Some @entity1 with residual @entity419 uptake will have a good outcome after HCT followed by ASCT. @entity419 PET is the imaging technique of choice for end-of-treatment evaluation. However, @entity419 is not specific for tumoral tissue. Active inflammatory lesions and infectious processes can be falsely interpreted as malignant residual cells. However, a negative @entity419 PET cannot exclude @entity41 . Consequently, it is always indicated to correlate PET findings with clinical data, other imaging modalities, and/or a biopsy. We calculated, from data of 17 studies in end-of-treatment evaluation, a sensitivity of 76%, a specificity of 94%, a @entity2286 of 82%, a NPV 92%, and an accuracy of 89%.

Evaluation of therapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity419 :: ('MESH:D019788', 'Chemical') :: ['(18)F-fluorodeoxyglucose', '(18)F-FDG'] @entity41 :: ('MESH:D018365', 'Disease') :: ['minimal residual disease'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma'] @entity2286 :: ('12211', 'Species') :: ['PPV']
@entity706 :: (MESH:D008223,Disease) :: ['lymphoma']
